How to De-Risk and Accelerate Your Drug Program to Clinical Trials.

This seminar will explore relevant solutions for accelerating nasal and oral clinical dosage form development.

Hosted by Dr Richard Johnson, Chief Scientific Officer at UK-based CDMO, Upperton Pharma Solutions, this seminar will cover formulation platforms, analytical characterisation techniques, and different particle engineering strategies to enhance drug success rates.

Key learning objectives

• Gain insights on strategies for reducing risks during nasal and oral clinical formulation development.
• Review drug product options for early clinical evaluation.
• Understand the potential advantages of spray drying to address solubility or particle engineering challenges.
• Network with other professionals.
• Speak with our experts during an interactive Q&A session.

Who should attend

• Pharmaceutical researchers and scientists.
• CMC experts on inhalation/nasal and oral drug delivery.
• Nasal and oral product development professionals.

Upperton Pharma Solutions is an award-winning UK-based CDMO, specializing in formulation development and clinical trial manufacturing for oral solids, liquids, semi-solids, nasal and inhaled drug products.